<rss version="2.0">
<channel>
<title>MindBranch: Pharmaceutical</title>
<description>Pharmaceutical market research products provide analysis of the latest trends, developments and market data for this industry.  Research information will help you make informed business decisions.</description>
<link>http://www.mindbranch.com/catalog/find.jsp?cat=ph</link>
<item>
<title>U.S. Regulatory Reporter</title>
<link>http://www.mindbranch.com/products/n198-001.html</link>
<description> <![CDATA[ This publication, the U.S. Regulatory Reporter Newsletter, is a monthly newsletter providing regulatory information for the pharmaceutical, medical and allied industries, and has been the primary source of FDA news for hundreds of regulatory and drug development professionals at pharmaceutical, financial, legal, and related companies worldwide. From CANDAs to NDA Days, and from emerging drug access programs to innovative vehicles for drug export, the U.S. Regulatory Reporter covers the FDA like no other periodical. Each monthly issue provides you with insights and in-depth articles, in addition to executive summaries of all FDA actions, including new proposed and final regulations, speeches by FDA officials, new product approvals, advisory committee meetings, and more.
  
 Biologics and Biotech Regulatory Report  
  
Each issue of the  U.S. Regulatory Reporter  includeds a special supplement specifically dedicated to CBER's regulation of biologics and biotechnology products: the  Biologics and Biotech Regulatory Report . From the new "managed ]]></description>
<pubDate>Tue, 01 Jul 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Us Markets For Women'S Health Imaging Systems</title>
<link>http://www.mindbranch.com/products/R192-439.html</link>
<description> <![CDATA[The total market for women&rsquo;s health imaging systems was valued at over $700 million in 2006. 
  

This market is comprised of breast imaging, obstetrics/gynecology (OB/GYN) ultrasound, bone densitometry, and computeraided detection (CAD) systems for breast ]]></description>
<pubDate>Fri, 09 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>New Directory: Top 60 Biopharmaceutical Manufacturers in INDIA</title>
<link>http://www.mindbranch.com/products/R631-14.html</link>
<description> <![CDATA[ The first edition of the BioPlan India Biopharmaceutical Index includes the Top 60 Biopharmaceutical Companies in India, with detailed profiles of their business focus, products, revenues, R&D and business strategies, international objectives, partnering strategies, and marketing activities. In addition, subscribers will receive on-going updates to activities and trends in India as the country&rsquo;s biopharmaceutical industry expands. Our India Biopharmaceutical Index and our Top 60 Directory provide you information on trending of activities and changes occurring in the region. Be sure to keep up-to-date on Who&rsquo;s Who in India. This report will help ensure you&rsquo;re current, and have a solid understanding of this dynamic, rapidly changing market. Our ranking of the Top 60 organizations is done using our proprietary profile analysis and assessment process. Over 300 pages profiling: Company Overview and History Senior Managers' Overview Ownership and Subsidiaries Detailed Financial Data Employee Data Partnering Opportunities Product Information Manufacturing Information International GMP ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>World OTC Pharmaceutical Markets: Self-Medication, Developing and Petro-Rich Economies, BTC and Other Growth Trends</title>
<link>http://www.mindbranch.com/products/R566-428.html</link>
<description> <![CDATA[Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions.  Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible.  Developing and petro-rich nations are pushing world demand for pharmaceuticals.  Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs.  The aging of the population and an increase in medical conditions generally continues to bode well for OTC products.

For the purpose of this study, Kalorama Information has divided products into five general segments: 

  Analgesics
 Allergy, Cough, Cold, Flu Remedies
 Gastrointestinal Remedies
 Dermatologics
 Others  (including: 	Smoking cessation products, Sleepaids, Dental rinses, fluorides, Hair growth remedies, Diet aids) 
As part of thorough coverage of the OTC market, this report includes: 
  
Current Market Size and Forecasts by Product Type
 Regional ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its Foreign Trade</title>
<link>http://www.mindbranch.com/products/R3418-2474.html</link>
<description> <![CDATA[ The Biological Product (except Diagnostic) Manufacturing Industry report provides in-depth analysis of the industry's  key financial data, cost and pricing, competitive landscape, industry structure, and trends and opportunities.    Find in this new report complete 2007 data and outlook into year 2012 for the industry represented by the 6-digit NAICS code 325414. This 155-page report also includes the most recent information on the global market and overseas growth opportunities.  This detailed information resource contains at least 5 years of independently researched industry statistics cross-referenced with the relevant U.S. and international economic indicators.  All data have been verified to ensure the highest quality.  In this report, you will find industry data on the following major categories:   Executive Summary       Quick Industry Statistics: 2-page overview for the CEO on the run     Supply & Demand with Capacity Utilization     2012 Outlook domestic and international        Industry Income Statement       All relevant financial data including: ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Soy Foods and Beverages in the U.S.</title>
<link>http://www.mindbranch.com/products/R567-643.html</link>
<description> <![CDATA[Although soy has been used in packaged food and beverage products for decades, it continues to make new inroads and increase its appeal among U.S. consumers, especially those interested in health and nutrition.  Particularly among natural food shoppers, there is a growing consensus that plant-based foods like soy, as opposed to animal-based foods, deliver unique, healthful benefits.  At the same time, soy continues to &ldquo;mainstream&rdquo; into regular supermarkets and new product categories, from smoothies and energy drinks to cereals and baked goods.  Helping to drive these trends, marketers are beginning to combine soy ingredients with other healthful ingredients, such as omega-3s and &ldquo;superfruits,&rdquo; to create unique products that are even more nutritious.  Moreover, as consumer awareness of the many health benefits of soy grows&mdash;especially its FDA-approved &ldquo;heart-healthy&rdquo; attributes&mdash;soy&rsquo;s use as an ingredient and attractiveness as a meal and snack choice can only increase.
 
This Packaged ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Major World Markets for Stents and The Economics of Drug-Eluting Technology</title>
<link>http://www.mindbranch.com/products/R566-427.html</link>
<description> <![CDATA[ 
Since the arrival of drug-eluting (called drug-eluding by some) technology a few years ago with the promise of reducing restenosis, questions abound surrounding the future of the stent market:  After numerous clinical studies and mixed cost-effectiveness results, how is drug-eluding technology expected to peform in the future? What can companies do to best market this technology in the healthcare system of the US and 6 other major world markets?  What are the market trends to watch that will determine growth in this field in the coming years?  What companies have already established a leadership position in stents and what do start ups have to do to join them?   Major World Markets for Stents and The Economics of Drug Eluding Technology , written by Kalorama Analyst Dr. Kenneth Krul, takes a hard look at these questions with economic analysis unmatched by any resource. The field of drug-eluting stents ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>State of the Clinical Trials Industry 2008</title>
<link>http://www.mindbranch.com/products/R423-368.html</link>
<description> <![CDATA[State of the Clinical Trials Industry 2008 edition offers the newest statistics on the clinical trials industry.  This comprehensive, easy-to-use resource includes over 600 charts and graphs of original, proprietary CenterWatch data examining all aspects of the global clinical trials industry. Also included are a review of the top clinical research stories of 2007 as reported by the editorial staff of The CenterWatch Monthly; as well as drug pipeline information and updates on specific disease areas. 

    

What&rsquo;s New in the 2008 Edition?
    Over 400 New and updated data charts 
 A new chapter featuring international developments  
 Summary highlights of key points from each chapter  
 An index of each charts and company mentioned 
 An expanded table of contents and list of figures    
 

State of the Clinical Trials Industry 2008 includes data on:
    Proprietary data ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Pharmaceutical Preparation Manufacturing Industry in the U.S. and its Foreign Trade</title>
<link>http://www.mindbranch.com/products/R3418-2473.html</link>
<description> <![CDATA[ The Pharmaceutical Preparation Manufacturing Industry report provides in-depth analysis of the industry's  key financial data, cost and pricing, competitive landscape, industry structure, and trends and opportunities.    Find in this new report complete 2007 data and outlook into year 2012 for the industry represented by the 6-digit NAICS code 325412. This 157-page report also includes the most recent information on the global market and overseas growth opportunities.  This detailed information resource contains at least 5 years of independently researched industry statistics cross-referenced with the relevant U.S. and international economic indicators.  All data have been verified to ensure the highest quality.  In this report, you will find industry data on the following major categories:   Executive Summary       Quick Industry Statistics: 2-page overview for the CEO on the run     Supply & Demand with Capacity Utilization     2012 Outlook domestic and international        Industry Income Statement       All relevant financial data including: Revenue, Cost ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Medicinal and Botanical Manufacturing Industry in the U.S. and its Foreign Trade</title>
<link>http://www.mindbranch.com/products/R3418-2472.html</link>
<description> <![CDATA[ The Medicinal and Botanical Manufacturing Industry report provides in-depth analysis of the industry's  key financial data, cost and pricing, competitive landscape, industry structure, and trends and opportunities.    Find in this new report complete 2007 data and outlook into year 2012 for the industry represented by the 6-digit NAICS code 325411. This 160-page report also includes the most recent information on the global market and overseas growth opportunities.  This detailed information resource contains at least 5 years of independently researched industry statistics cross-referenced with the relevant U.S. and international economic indicators.  All data have been verified to ensure the highest quality.  In this report, you will find industry data on the following major categories:   Executive Summary       Quick Industry Statistics: 2-page overview for the CEO on the run     Supply & Demand with Capacity Utilization     2012 Outlook domestic and international        Industry Income Statement       All relevant financial data including: Revenue, ]]></description>
<pubDate>Thu, 01 May 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Chiropractor Offices</title>
<link>http://www.mindbranch.com/products/R3470-1323.html</link>
<description> <![CDATA[The US chiropractic industry includes about 30,000 firms with combined annual revenue of $7 billion. Most are one-office firms, but about 300 firms operate multiple offices. The industry is highly fragmented: the average chiropractic office has annual revenue under $250,000.   COMPETITIVE LANDSCAPE  Demand for chiropractic services is driven by the aging US population and growing interest in alternative medicine. Profitability of individual practices depends largely on marketing. The industry is labor-intensive, with annual revenue per worker of $80,000. Chiropractors compete with physical therapists and medical doctors, many of whom consider chiropractic treatments ineffective.   PRODUCTS, OPERATIONS & TECHNOLOGY  Chiropractors treat mainly patients who have pain due to muscular or skeletal injuries; back pain is the most common complaint. Treatment commonly consists of &quot;spinal manipulative therapy&quot; (SMT), based on the theory that the pain is due to misaligned bones (&quot;subluxations&quot;) that interfere with the nervous system. Treatment usually includes a series of &quot;adjustments.&quot; Many ]]></description>
<pubDate>Mon, 28 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Slovenia Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3057.html</link>
<description> <![CDATA[Despite being smaller and more mature than most of its Central and Eastern European (CEE) peers,Slovenia still offers considerable commercial opportunities within its pharmaceutical market. Most of thegrowth over the coming years is set to be driven by the introduction and use of more advanced treatments,despite the government&rsquo;s attempt to control pharmaceutical spending by placing limits on prescribing andsimilar measures. In addition, the fact that most branded generics enjoy relatively high prices in relationto original products will support this upward trend.  In the meantime, the high incomes of a substantial proportion of the population will also be positivelyreflected in the growth of the over-the-counter (OTC) segment, especially as consumers become morehealth conscious. The government&rsquo;s programme for reducing the use of hospitals, as well as an attempt toaddress overprescribing, will also result in the development of the OTC market.   The Slovenian medical devices market is relatively advanced in relation to its CEE ]]></description>
<pubDate>Thu, 24 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Slovakia Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3058.html</link>
<description> <![CDATA[Slovakian pharmaceutical market remains one of the less attractive markets amongst its Central andEastern European (CEE) peers, primarily due to its small size and a sizeable healthcare debt, despite arelatively favourable business environment. However, the new left-leaning government, elected in 2006,has passed a basket of measures in an attempt to achieve a better financial balance, although some of thechanges have been strongly opposed. Most recently, the government banned profit-making in thehealthcare insurance sector, with the aim of freeing up more funds for patients&rsquo; needs, but alsodisincentivising the companies in the sector by removing competition and essentially their reason foroperating.  In terms of market segmentation, the generics market represents around a quarter of the total by value.However, the new anti-Bolar (and thus anti-EU legislation) law threatens to delay the entry of copyproducts onto the market over the coming years, to the detriment of the local as well as internationalgenerics players. In the ]]></description>
<pubDate>Thu, 24 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Croatia Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3011.html</link>
<description> <![CDATA[The Croatian pharmaceutical market has developed strongly in the past decade, but remains small in 
regional terms, given the limitations posed by the small population size. Generics, mostly of the relatively 
expensive branded variety, account for over 70% of the total prescription market by value. The use of 
novel and more expensive pharmaceuticals is hampered by healthcare debts, cost-containment initiatives 
and the support for the strong domestic generics industry in the face of distinct intellectual property (IP) 
deficiencies. In the coming years, however, regulatory and healthcare service improvements, as well as 
the increasing number of prescriptions, are set to gradually facilitate market entry for such products, 
especially as Croatian European Union (EU) membership talks reach later stages.   
Generally speaking, the forecast period will witness a continued dominance of prescription medicines, 
although over-the-counter (OTC) drugs are rapidly gaining prominence, boosted by marketing and 
information campaigns. Value growth of the sector will, ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Czech Republic Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3012.html</link>
<description> <![CDATA[n March 2008, we updated all data for the 59 countries surveyed with official figures, sourced from 
central banks and regulators. In most cases, we were able to find data that pertained to the end of 2007: in 
almost all other cases, the data pertains to September 30 2007. As a result, the insights that we derive on 
particular countries are based on consistently sourced information that is far more current than it had been 
previously.   
Although we gather data for countries such as the US, Japan, Australia and the eurozone, the vast 
majority of the 59 countries whose banking industries we survey are, or are generally seen as being, 
emerging markets. For all the widely publicised problems of large banks in developed countries, in the 
wake of the subprime banking crisis in the US, 2007 was an extremely good year for the banking sectors 
of the emerging markets. In ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Lebanon Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3035.html</link>
<description> <![CDATA[Lebanon&rsquo;s pharmaceutical market continues to be adversely affected by internal instability - first the 
2006 conflict with Israel and more recently the lack of political leadership. The 2006 war severely dented 
Lebanon&rsquo;s infrastructure, while the uncertain political situation continues to deter foreign investment. 
Lebanon&rsquo;s pharmaceutical market was estimated to be worth US$472mn in 2007. Growth is expected to 
remain subdued, averaging 4% year-on year (y-o-y) through the forecast period.   
Healthcare provision is dominated by the private sector, with only 8% of the population benefiting from 
government-run primary care facilities. Political instability appears to be aiding the development of the 
private sector as the public system is hampering the function of the public sector. Hospitals remain the 
main place where patients access healthcare meaning prescription drugs should continue to dominate the 
market. However, rising health awareness should lead to stronger growth in the over-the-counter (OTC) 
drug market - particularly in the ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Belgium Pharamceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3077.html</link>
<description> <![CDATA[Belgium&rsquo;s pharmaceutical market was worth US$4.89bn in 2007 and should grow steadily over the
forecast period to reach a value of US$5.67bn by 2012. Patented drugs are the leading category,
accounting for almost 80% of the market; however, generic drugs are the fastest-growing sector, as the
government seeks to promote these products as part of cost-saving plans.  
This focus on saving is beginning to pay of and this quarter the government announced that expenditure
on reimbursed drugs remained within budget. This was primarily due to an increase in the uptake of lowcost
drugs. In 2007, over 40% of prescriptions for reimbursed medicines were for low-cost
pharmaceuticals. Breaking this down, generic medicines accounted for 23.54% of the total, while
originator drugs that have lost their patents and have had their prices reduced accounted for 16.69%.
Meanwhile, drugmakers in Belgium should benefit from a European Commission (EC) decision to
authorise a series ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Saudi Arabia Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3034.html</link>
<description> <![CDATA[Saudi Arabia&rsquo;s drug market was estimated to be worth US$1.95bn in 2007, accounting for a little under 
60% of the Gulf Co-operation Council (GCC) region&rsquo;s market. BMI forecasts 6.5% year-on-year (y-o-y) 
growth. Pharmaceutical demand should be driven by modernisation of the healthcare sector and rapid 
population growth. However, government moves to control drug prices through mandatory price 
reductions could serve to limit growth in the sector.   
Patented drugs should remain dominant over the forecast period and as a consequence, the pharmaceutical 
trade balance should remain negative. However, the generics market is expected to gradually increase its 
market share from 5.6% in 2007 to 8.6% by 2012. At the same time, the country&rsquo;s underdeveloped overthe- 
counter (OTC) sector should continue to expand, fuelled by improved disease awareness among 
citizens.   
As the largest pharmaceutical market in the region, recently-relaxed laws on foreign ownership, which 
now allow 100% foreign equity investment, could see ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3033.html</link>
<description> <![CDATA[The United Arab Emirates (UAE) represents the most attractive market in the Middle East and Africa 
(MEA) region, despite not being the largest in size. Key factors driving the growth of the country&rsquo;s 
pharmaceutical volumes and values in the coming years include increasing public and private wealth 
fuelled by the oil boom, strong and strengthening healthcare infrastructure, approvals of more medicines, 
a friendly regulatory environment and the absence of significant local competitors. Consequently, the 
UAE retains its pole position in BMI&rsquo;s Business Environment Rankings for the Middle East and Africa 
(MEA) region for Q208.   
However, while the market is expected to top US$1.19bn in value in 2012, annual growth rates will be 
dependent on a number of developments. Despite its tough stance on pricing, the Ministry of Health is 
fearful of the low profits affecting the availability of drugs in the UAE. Nevertheless, in November 2007, 
the government announced its ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Mexico Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3026.html</link>
<description> <![CDATA[BMI has upgraded its five-year value-growth forecast for the Mexican pharmaceutical market for 2007 - 
2012 from an average rate of 5.5% per annum to 6.6%. Increased government spending and enabling 
legislation aimed to achieve earlier commitments to eliminate copy drugs or similares by forcing 
producers to present comprehensive efficacy and safety data is expected to push up the value of the 
legitimate generics market. BMI expects an 8.7% US dollar growth in the total market of consumer prices 
in 2008, with a total value of US$14.8bn, putting per capita consumption at US$123.2mn.   
Also, in this quarter BMI introduces coverage of the Mexican medical device market, another sector 
posed for strong growth on the back of improved healthcare coverage. Mexico's medical device market is 
the second largest in Latin America after Brazil, and BMI forecasts it will outpace pharmaceutical market 
growth to reach US$3.38bn by 2012. Local market growth and ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Indonesia Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3020.html</link>
<description> <![CDATA[While Indonesia&rsquo;s healthcare indicators have improved in recent years, in line with economic 
development, the country remains one of the poorest in its immediate neighbourhood. Nevertheless, the 
fact that people are living longer means that fewer individuals of wage-earning age are dying and more 
children are surviving, which is resulting in a more buoyant workforce. Therefore, despite the low per 
capita consumption of pharmaceuticals, rising population numbers should boost demand for medical 
services, resulting in the pharmaceutical market reaching the value of US$3.75bn in 2012, growing at 
around 5-6% per annum. Sales of traditional herbal medicines, known as jamu, are expected to 
considerably outpace those of conventional pharmaceuticals in terms of annual growth, threatening the 
value of the over-the-counter (OTC) sector.   
However, benefits of healthcare sector modernisation will largely be negated by the deficiencies of the 
country&rsquo;s patent protection and sizeable counterfeit industry. Foreign companies will also be 
disadvantaged by ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Taiwan Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3019.html</link>
<description> <![CDATA[Taiwan represents a pharmaceutical market of moderate interest to multinational pharmaceutical firms 
operating in the Asia Pacific region. The draws of the US$4.32bn market include a traditional preference 
for branded medicines, a strong research environment - especially in the field of biotechnology - and a 
highly urbanised population. However, several recent price cuts and a less than clear operating 
environment provide a degree of concern. Consequently, Taiwan retains seventh position in BMI&rsquo;s 
Pharmaceutical Business Environment Ranking table for Q208 out of the 14 regional markets surveyed. 
While BMI is expecting reasonable market growth, to around US$5.29bn by 2012, considerable 
challenges will be presented by the new regulatory requirements. In November 2007, Taiwan introduced 
a health technology assessment (HTA) system for pricing and reimbursement of new drugs. Specifically, 
prior to evidence evaluation, the proposed price of a new pharmaceutical will be benchmarked using 
existing prices in 10 other markets. HTA tools ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Spain Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3015.html</link>
<description> <![CDATA[Spain&rsquo;s drug market was worth US$16.58bn in 2007 and is forecast to reach US$18.9bn in value by 
2012, representing a compound annual growth rate (CAGR) of 2.65%, which is hardly stellar but is 
perhaps understandable in light of the period of economic cooling that the country is likely to experience 
in the next few years. The generics sector is showing the most robust growth, which should reach a value 
of US$1.04bn by 2012, however the fact that it is growing from a low base is limiting its impact on the 
overall market.   
In Q208, BMI has included Spain&rsquo;s medical device sector in its coverage for the first time. Following 
rapid growth in the early part of the decade, the market reached an estimated value of US$3.9bn in 2007. 
Although the sector is still expanding at a brisk pace in local currency terms, exchange rate considerations 
have affected the market in ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>United Kingdom Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3014.html</link>
<description> <![CDATA[The UK is one of the leading drug markets in Western Europe and should continue to develop strongly 
over the forecast period to reach a value of GBP34.4bn. Strengths include the de-regulated over-thecounter 
(OTC) market as well as continuing demand for patented pharmaceuticals. The country&rsquo;s 
scientific infrastructure and research capabilities are also world-class, being outmatched in many areas 
only by the US.   
However, the Association of the British Pharmaceutical Industry (ABPI) claims that plans to re-negotiate 
the Pharmaceutical Pricing Regulation Scheme (PPRS) is creating a more uncertain environment for 
drugmakers. According to a recent survey of 100 British pharmaceutical companies conducted by the 
ABPI and the Confederation of British Industry (CBI), more than one-third are expecting to reduce the 
level of R&D spending in the country and nearly half expect the number of clinical trials to drop. 
Meanwhile pessimism seems at an all time high with 83% of companies expecting ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
<item>
<title>Germany Pharmaceuticals and Healthcare Report Q2 2008</title>
<link>http://www.mindbranch.com/products/R302-3013.html</link>
<description> <![CDATA[Germany&rsquo;s pharmaceutical market was worth approximately US$48.9bn in 2007, making it the largest in 
Europe. Unsurprisingly, for such a mature market, growth will be steady rather than spectacular, with 
drug expenditure reaching a value of US$57.2bn in 2012. This represents a compound annual growth rate 
(CAGR) of 3.19%.   
The biggest change this quarter has been BMI&rsquo;s introduction of forecasts in the medical device market. In 
2007, we estimated that the medical equipment market was worth approximately US$13bn and should 
reach a value of US$15.1bn by 2012. This represents a CAGR of 3%, a slightly lower rate than the 
pharmaceuticals market. Going forward, growth should be driven primarily by large, top-end medical 
equipment due to Germany's technological sophistication in this area.   
Elsewhere, Germany's drug discount contracts have come under fire from the German Association of 
Medicines Manufacturers (BAH), which claims that they are anti-competitive and will hurt small and 
medium-sized enterprises. ]]></description>
<pubDate>Tue, 22 Apr 2008 00:00:00 EST</pubDate>
</item>
</channel>
</rss>
